Cantor Fitzgerald Weighs in on CG Oncology FY2026 Earnings

CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Cantor Fitzgerald issued their FY2026 earnings estimates for shares of CG Oncology in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($3.58) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $75.00 price objective on the stock. The consensus estimate for CG Oncology's current full-year earnings is ($1.31) per share.

CG Oncology (NASDAQ:CGON - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.09). CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. The company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.53 million.

A number of other research analysts also recently commented on the stock. Royal Bank of Canada increased their price objective on shares of CG Oncology from $66.00 to $68.00 and gave the company an "outperform" rating in a research note on Tuesday, April 29th. Morgan Stanley dropped their target price on shares of CG Oncology from $55.00 to $52.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. JPMorgan Chase & Co. started coverage on shares of CG Oncology in a report on Friday, May 2nd. They set an "overweight" rating and a $41.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $75.00 target price on shares of CG Oncology in a report on Monday, April 28th. Finally, Scotiabank started coverage on shares of CG Oncology in a report on Wednesday, April 16th. They set a "sector perform" rating and a $23.00 target price on the stock. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, CG Oncology has a consensus rating of "Buy" and an average target price of $58.22.

CG Oncology Trading Down 2.4%

NASDAQ CGON traded down $0.64 during trading hours on Wednesday, reaching $25.86. 626,383 shares of the company traded hands, compared to its average volume of 837,930. CG Oncology has a 12 month low of $14.80 and a 12 month high of $40.47. The stock has a market capitalization of $1.97 billion, a PE ratio of -17.13 and a beta of 0.86. The company has a 50 day moving average of $24.04 and a two-hundred day moving average of $26.83.

Institutional Trading of CG Oncology

A number of large investors have recently modified their holdings of CGON. Foresite Capital Management VI LLC acquired a new stake in shares of CG Oncology in the 4th quarter worth about $63,712,000. Marshall Wace LLP grew its position in CG Oncology by 18,836.0% in the 4th quarter. Marshall Wace LLP now owns 1,458,072 shares of the company's stock valued at $41,818,000 after buying an additional 1,450,372 shares in the last quarter. Wellington Management Group LLP grew its position in CG Oncology by 274.4% in the 4th quarter. Wellington Management Group LLP now owns 1,910,470 shares of the company's stock valued at $54,792,000 after buying an additional 1,400,251 shares in the last quarter. Acorn Capital Advisors LLC bought a new position in CG Oncology in the 4th quarter valued at about $32,451,000. Finally, Decheng Capital LLC grew its position in CG Oncology by 16.3% in the 4th quarter. Decheng Capital LLC now owns 6,371,669 shares of the company's stock valued at $182,739,000 after buying an additional 892,859 shares in the last quarter. Institutional investors and hedge funds own 26.56% of the company's stock.

Insider Buying and Selling

In related news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $30.76, for a total value of $30,760.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 7.40% of the company's stock.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.